--ON HOLD-- New potential radiosensitizer for canine intranasal tumors

Email icon Pre-Screen here button

Purpose and brief explanation of the study

The purpose of this study is to assess the safety and effectiveness of a new treatment to enhance response to radiation therapy for dogs with stage 3 intranasal adenocarcinoma.

What qualifies my pet for enrollment?

  • Dogs with a diagnosis of stage 3 intranasal adenocarcinoma
  • No prior chemotherapy, radiotherapy, or surgery to treat their condition.
  • Dogs ≥ 1 year (12 months) of age.
  • Body weight: > 5 kg.
  • No evidence of metastatic disease
  • No other major health problems

What does enrolling my pet in this clinical trial involve?

Your dog will be received 5 daily (Monday-Friday) fractions of palliative-intent radiation therapy and performed under general anesthesia - this is a standard of care for canine nasal tumors. Either the investigational treatment or a placebo will be administered intravenously prior to each radiation treatment. Your dog will be required to return to the VMC for a recheck appointment 4 weeks later. A skull CT will be performed at week 13 post-treatment to evaluate the tumor response. You will also be asked to complete some questionnaires related to your dog’s quality of life over the course of the study.

Client compensation

Eligible dogs that enroll will receive financial compensation of $1,000 to assist with costs associated with treatment of their tumor and a skull CT scan at week of 13 to monitor for disease progression will also be covered by the study.